Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
5(100.0%)
5Total
Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06874621Phase 1Active Not Recruiting

VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease

Role: lead

NCT03562494Phase 1Completed

VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)

Role: collaborator

NCT03733496Completed

Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies

Role: collaborator

NCT03065192Phase 1Completed

Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease

Role: collaborator

NCT04885114Phase 1Withdrawn

Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's Disease

Role: lead

NCT01973543Phase 1Completed

Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease

Role: collaborator

All 6 trials loaded